Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer

Hsian Yu Wang, Yu Ling Chang, Chun Chun Cheng, Min Wu Chao, Su I. Lin, Shiow Lin Pan, Chih Cheng Hsu, Tsang Wu Liu, Han Chin Cheng, Ching-Ping Tseng, Shih Jen Liu, Hui Ju Tsai, Hsing Yi Chang*, John T.A. Hsu


研究成果: Article同行評審

6 引文 斯高帕斯(Scopus)


The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.

頁(從 - 到)85917-85928
出版狀態Published - 1 1月 2016


深入研究「Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer」主題。共同形成了獨特的指紋。